Search

Displaying results 4131 - 4140 of 10000 in total
  1. Drug

    Dodecyltrimethylammonium

    go.drugbank.com/drugs/DB02779
    Experimental

    Synonyms: N,N,N-Trimethyl-1-dodecanaminium, n-DodecyltrimethylammoniumCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Calcium oxide

    go.drugbank.com/drugs/DB15648
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation.

  4. Drug

    Propatyl nitrate

    go.drugbank.com/drugs/DB13255
    Investigational

    Categories: Vasodilators Used in Cardiac Diseases
  5. Drug

    Terbutryn

    go.drugbank.com/drugs/DB08215
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Enalkiren

    go.drugbank.com/drugs/DB03395
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  7. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult

  8. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  9. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the … [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]

  10. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in … (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B.